Abstract 387P
Background
The prevalence of tobacco use has significant implications for the global economy, since it is the leading cause of death and disease worldwide. Currently, tobacco-related factors contribute to an estimated 8 million deaths annually, with a majority of these fatalities concentrated in low- and middle-income countries. The objective of this study was to perform a thorough evaluation of existing literature concerning tobacco use and cancer prevalence across Indian tribal tribes, with the aim of ascertaining the prevalence, distribution, and factors that contribute to tobacco use, which is necessary for the purpose of developing and modifying control strategies aimed at mitigating tobacco consumption among this marginalized community.
Methods
A systematic review was undertaken to examine the available evidence on the oral health status, tobacco use, and cancer prevalence among tribal groups in India. The review was registered in the PROSPERO database. Sources published from 1980 to 2023 from reputable databases like PubMed, Crossref, Google Scholar, and Web of Science were used in this evaluation.
Results
The findings of this study encompass a comprehensive analysis of 22 distinct tribal population involving 28,572 individuals. The prevalence of tobacco consumption varied between 12% and 42.5%. In the context of gender-specific studies, the prevalence of tobacco use among females varied between 1.2% and 12%, whereas among males it ranged from 15% to 52%. The prevalence of oral cancer in this marginalized community ranged from 5% to 12%, as assessed. In contrast, the consumption of smokeless tobacco was prevalent throughout the indigenous community. The primary risk factors for tobacco use were identified as a dearth of information regarding oral health, deeply entrenched dental attitudes, and limited accessibility to health services.
Conclusions
To effectively address the issue of tobacco use, it is imperative to prioritize additional research on improved methodologies, evidence-based policies, and viable options for tobacco cessation. This review recommends implementing campaigns and abstinence as an effective strategy for mitigating the adverse consequences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract